Back
Return
Biography
Prof. Ramón Cacabelos

Prof. Ramón Cacabelos

Camilo José Cela University, Spain

 

Email: rcacabelos@euroespes.com

 

Qualifications

1985 Ph.D., Doctor in Medicine and Surgery, Santiago University Medical School, Santiago de Compostela, Spain

1980 M.D., Graduate in Medicine and Surgery. Oviedo University Medical School, Oviedo, Spain

 

Publications (Selected)

  1. Cacabelos, R., Álvarez, X.A., Fernández-Novoa, L., Lombardi, V.R.M. A pharmacogenomic approach to Alzheimers disease. Acta Neurol. Scand., 102 (Suppl. 176):12-19 (2000).
  2. Cacabelos, R. Psychogeriatric research: A conceptual introduction to aging and geriatric neuroscience. Psychogeriatrics, 1:158-188 (2001).
  3. Cacabelos, R. Pharmacogenomics in Alzheimers disease. Min. Rev. Medic. Chem., 2:59-84 (2002).
  4. Cacabelos, R. Pharmacogenomics for the treatment of dementia. Ann. Med., 34:357-379 (2002).
  5. Cacabelos, R. The application of functional genomics to Alzheimers disease. Pharmacogenomics, 4:597-621 (2003).
  6. Cacabelos, R., Fernández-Novoa, L., Lombardi, V., Corzo, L., Pichel, V., Kubota, Y. Cerebrovascular risk factors in Alzheimers disease: Brain hemodynamics and pharmacogenomic implications. Neurol. Res., 25:567-580 (2003).
  7. Cacabelos, R., Corzo, L., Fernández-Novoa, L., Lombardi, V. Histamine in Alzheimers disease pathogenesis: Biochemistry and functional genomics. Meth. Find. Exp. Clin. Pharmacol., 26(Suppl. 2):9-16 (2004).
  8. Cacabelos, R., Fernández-Novoa, L., Corzo, L., Pichel, V., Lombardi, V., Kubota, Y. Genomics and phenotypic profiles in dementia: Implications for pharmacological treatment. Meth. Find. Exp. Clin. Pharmacol., 26:421-444 (2004).
  9. Cacabelos, R., Fernández-Novoa, L., Corzo, L., Amado, L., Pichel, V., Lombardi, V., Kubota, Y. Phenotypic profiles and functional genomics in Alzheimers disease and in dementia with a vascular component. Neurol. Res., 26:459-480 (2004).
  10. Cacabelos, R. Genomic characterization of Alzheimers disease and genotype-related phenotypic analysis of biological markers in dementia. Pharmacogenomics, 5:1049-1105 (2004).
  11. Cacabelos, R., Fernández-Novoa, L., Lombardi, V., Kubota, Y., Takeda, M. Molecular genetics of Alzheimers disease and aging. Meth. Find. Exp. Clin. Pharmacol., 27(Suppl. A):1-573 (2005).
  12. Cacabelos, R. Pharmacogenomics, nutrigenomics and therapeutic optimization in Alzheimers disease. Aging Health, 1:303-348 (2005).
  13. Cacabelos, R. Pharmacogenomics and therapeutic prospects in Alzheimers disease. Expert Opin. Pharmacother., 6:1967-1987 (2005).
  14. Cacabelos, R., Takeda, M. Pharmacogenomics, nutrigenomics and future therapeutics in Alzheimers disease. Drugs Future, 31(Suppl. B):5-146 (2006).
  15. Cacabelos, R. Molecular pathology and pharmacogenomics in Alzheimers disease: Polygenic-related effects of multifactorial treatments on cognition, anxiety, and depression. Meth. Find. Exper. Clin. Pharmacol., 29(Supp. A):1-91 (2007).
  16. Takeda, M., Cacabelos, R. (Eds.). Alzheimers disease genomics. Cognition and Dementia, 6 (Suppl.):7-113 (2007).
  17. Cacabelos, R. Donepezil in Alzheimers disease: From conventional trials to pharmacogenetics. Neuropsychiat. Dis. Treat., 3:303-333 (2007).
  18. Cacabelos, R., Llovo, R., Fraile, C., Fernández-Novoa, L. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: The role of CYP2D6 in Alzheimers disease pharmacogenetics. Cur. Alzheimer Res., 4:479-500 (2007).
  19. Cacabelos, R. Pharmacogenetic basis for therapeutic optimization in Alzheimers disease. Mol. Diag. Ther., 11:385-405 (2007).
  20. Cacabelos, R. Pharmacogenomics and therapeutic prospects in dementia. Eur. Arch. Psychiatry Clin. Neurosci., 258(Suppl. 1):28-47 (2008).
  21. Cacabelos, R. Influence of pharmacogenetic factors on Alzheimers disease therapeutics. Neurodegenerative Dis., 5:176-178 (2008).
  22. Cacabelos, R. Pharmacogenomics in Alzheimers disease. Meth Mol. Biol., 448:213-357 (2008).
  23. Cacabelos, R. Pharmacogenomics in Alzheimers disease. In: Pharmacogenomics and Personalized Medicine. Cohen, N. (Ed.). pp. 317-368 (2008).
  24. Cacabelos, R. Pleiotropic effects of Apolipoprotein E in dementia: Influence on functional genomics and pharmacogenetics. Adv. Behav. Biol., 57:355-367 (2008).
  25. Cacabelos, R. Pharmacogenomic Biomarkers in Neuropsychiatry: The Path to Personalized Medicine in Mental Disorders. In: The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes. Vol. IV: Molecular Genetic and Genomic Markers. Ritsner, M.S. (Ed.). Springer, pp. 3-63 (2009).